Table 1.
Comparison of populations and outcomes for high risk human papillomavirus (hrHPV) testing versus liquid based cytology (LBC) in the baseline (prevalence) screening round. Values are numbers (percentages) unless stated otherwise
| Characteristic | hrHPV | LBC | Odds ratio for hrHPV testing v LBC (95% CI) | ||
|---|---|---|---|---|---|
| Unadjusted | Adjusted* | ||||
| Total | 183 970 (100) | 394 577 (100) | NA | NA | |
| Age at screening (years): | |||||
| 24-29 | 35 085 (19) | 75 847 (19) | NA | NA | |
| 30-49 | 105 365 (57) | 226 034 (57) | NA | NA | |
| 50-64 | 43 520 (24) | 92 696 (23) | NA | NA | |
| IMD deciles at screening: | |||||
| 1-5 (most deprived) | 93 001 (51) | 229 576 (58) | NA | NA | |
| 6-10 (least deprived) | 90 969 (49) | 165 001 (42) | NA | NA | |
| Procedures (% screened)†: | |||||
| Positive screening test outcomes requiring additional testing | 23 331 (12.7)‡ | 15 121 (3.8)§ | 3.64 (3.57 to 3.72) | 3.90 (3.81 to 3.98) | |
| Immediate referrals¶ | 7724 (4.2) | 15 117 (3.8) | 1.10 (1.07 to 1.13) | 1.14 (1.11 to 1.17) | |
| Referrals after repeated testing¶ | 5070 (2.8) | NR | NR | NR | |
| Total referral** | 13 010 (7.1) | 18 205 (4.6) | 1.57 (1.54 to 1.61) | 1.61 (1.57 to 1.65) | |
| Total colposcopies** | 12 559 (6.8) | 16 378 (4.2) | 1.69 (1.65 to 1.73) | 1.77 (1.73 to 1.82) | |
| Histological outcomes, after immediate referral (% screened)†¶: | |||||
| CIN2+ | 3060 (1.7) | 5932 (1.5) | 1.11 (1.06 to 1.16) | 1.12 (1.07 to 1.17) | |
| CIN3+ | 1939 (1.1) | 3753 (1.0) | 1.11 (1.05 to 1.17) | 1.12 (1.06 to 1.19) | |
| Cervical cancer | 89 (0.1) | 167 (0.0) | 1.14 (0.88 to 1.48) | 1.14 (0.88 to 1.48) | |
| Histological outcomes including immediate referral and early recall (% screened)† ††: | |||||
| Normal biopsy | 6284 (3.4) | 7126 (1.8) | 1.92 (1.86 to 1.99) | 1.98 (1.91 to 2.05) | |
| CIN1 | 2039 (1.1) | 2780 (0.7) | 1.58 (1.49 to 1.67) | 1.71 (1.62 to 1.82) | |
| CIN2+ | 4156 (2.3) | 6113 (1.6) | 1.47 (1.41 to 1.53) | 1.49 (1.43 to 1.55) | |
| CIN3+ | 2521 (1.4) | 3833 (1.0) | 1.42 (1.35 to 1.49) | 1.44 (1.36 to 1.51) | |
| Cervical cancer | 101 (0.1) | 170 (0.0) | 1.27 (1.00 to 1.63) | 1.27 (0.99 to 1.63) | |
NA=not applicable; IMD=index of multiple deprivation; NR=not relevant; CIN2+=cervical intraepithelial neoplasia grade 2 or worse; CIN3+=cervical intraepithelial neoplasia grade 3 or worse; CIN1=cervical intraepithelial neoplasia grade 1.
Adjusted for age (years), IMD decile, and laboratory.
See supplementary figure 1A for hrHPV and 1B for LBC.
hrHPV positive with a known cytological outcome.
hrHPV positive low grade abnormal cytology or high grade abnormal cytology regardless of the hrHPV status.
Per protocol, in women with a record of referral to the specific type of follow-up (see supplementary figure 1A).
Counted as one per woman, including referrals or colposcopies conforming to the screening recommendations and colposcopies in women with screening test results for which the screening recommendations did not include a referral for colposcopy.
Includes biopsies taken per protocol (colposcopy after immediate referral or after early recall at 12 and 24 months), and biopsies taken outside of the protocol (see supplementary figure 1).